HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Release of reimbursement data a shaky step toward transparency
• Study results guide decisions about local therapy for breast cancer Douglas Yee, MD
• High BMI linked with poorer survival in pre-, post-menopausal breast cancers
• One-quarter of breast cancer survivors reported financial decline after treatment
• The role of imaging in recurrent vulvar carcinoma Deborah Zelinsky, OD, FNORA, FCOVD; Matthew J. Bollier, MD; Munir Ghesani, MD, FACNM; Grigorios Chrysofakis, MD
• Survivors of AYA bone, soft tissue sarcoma at risk for long-term mortality
• Patients with hematologic malignancies received more aggressive end-of-life care
• Rituximab, chlorambucil may benefit certain patients with CLL
• Guidelines target pulmonary hypertension in patients with sickle cell disease
• Acute pancreatitis may be predictor of pancreatic adenocarcinoma
• Breast conservation therapy extended disease-specific survival in early-stage invasive ductal carcinoma
• Breast-conserving therapy did not increase risk for local recurrence in triple-negative disease
• Hyperfractionated radiation improved outcomes in head and neck cancers
• IMRT superior to 3D-CRT in oropharyngeal squamous cell carcinoma
• Individualized risk assessment would increase mammography’s benefit
• Chemoradiation extended OS in oropharyngeal cancer
• Children with cancer exhibited no increased risk for PTSD
• Consolidation with arsenic trioxide averted maintenance therapy in APL
• Daily aspirin use reduced ovarian cancer risk by 20%
• Erlotinib plus cisplatin chemoradiation induced high response rate in cervical cancer
• First-line bevacizumab failed to improve OS in newly diagnosed glioblastoma
• Glutathione failed to prevent chemotherapy-induced peripheral neuropathy
• Multitarget stool DNA testing increased colorectal cancer detection
• No link observed between tea consumption, liver cancer
• Sibling, unrelated-donor HSCT conferred similar survival in DLBCL
• Stereotactic radiation for prostate cancer lowered costs, increased toxicity
• Uterine cancer radiation increased risk for bladder cancer
• Radiofrequency ablation reduced risk for esophageal adenocarcinoma
• Genomic testing has ‘transformed’ lung cancer care
• Increased circulating tumor cells predicted shorter OS in prostate cancer
• Malignancies increased risk for non-leg DVT
• Restrictive red blood cell transfusion regimen lowered risk for HAI
• Vemurafenib extended survival in BRAF V600-positive melanoma
• EML4-ALK fusion testing, targeted crizotinib treatment not cost-effective in NSCLC
• ASH presents ‘bridge grants’ to 15 hematology researchers
• BMT society presents lifetime achievement award
• City of Hope appoints new surgical chair
• Cetuximab plus chemoradiation failed to improve OS in esophageal cancer
• Obesity linked to mortality in premenopausal, ER-positive early breast cancer
• Afatinib extended OS in EGFR-mutated NSCLC
• Brain, neck tumors reported in 3 dozen cath lab operators
• Novel EGFR inhibitor safe, effective in EGFR-resistant NSCLC
• Pembrolizumab induced high rates of durable responses in advanced melanoma
• Drug combination highly active in recurrent ovarian cancer
• Immediate ADT offers little OS benefit for PSA-detected prostate cancer relapse
• Novel small-molecule inhibitor shows promise for pigmented villonodular synovitis
• Exemestane superior to tamoxifen for early-stage breast cancer
• Long-term CML management requires routine assessments for toxicities, adherence Debbie Blamble, PharmD, BCOP